|Year : 2010 | Volume
| Issue : 3 | Page : 241-244
Detection and characterization of metallo beta lactamases producing Pseudomonas aeruginosa
A Manoharan1, S Chatterjee1, D Mathai1, SARI Study Group2
1 Benjamin M Pulimood Laboratories for Infection, Immunity and Inflammation (BMPLIII), Department of Medicine Unit I and Infectious Diseases, Christian Medical College, Vellore -632004, Tamil Nadu, India
2 Surveillance of Antimicrobial Resistance in India Study Group (SARISG), Kothari Medical Center, Kolkata - Dr. Anuradha Aggarwal; Mahatma Gandhi Institute of Medical Sciences, Wardha - Dr. Vijayshree Deotale & Dr. D. K. Mendiratta; P D Hinduja Hospital, Mumbai - Dr. Camilla Rodriguez; Sri Ramachandra Medical College, Chennai - Dr. Padma Srikanth; Sir Gangaram Hospital, New Delhi - Dr. Chand Wattal; Sundaram Medical Center, Chennai - Dr. Vaidehi & Dr. Ram Rajagopal; Tata Memorial Center, Mumbai - Dr. Rohini Kelkar, India
|Date of Submission||28-Sep-2009|
|Date of Acceptance||13-Jan-2010|
|Date of Web Publication||17-Jul-2010|
Benjamin M Pulimood Laboratories for Infection, Immunity and Inflammation (BMPLIII), Department of Medicine Unit I and Infectious Diseases, Christian Medical College, Vellore -632004, Tamil Nadu
Source of Support: CIPLA India, Conflict of Interest: None
This study was undertaken to evaluate phenotypic and genotypic methods for detection of Metallo-Beta-Lactamases (MBLs) among nosocomial Pseudomonas aeruginosa. Sixty one among 176 P. aeruginosa isolates, collected as part of a multicentric study (2005-2007), were evaluated for carbapenem resistance (CARB-R; resistant to either imipenem/meropenem) and screened for MBL by Combination Disk Diffusion Test (CDDT) using imipenem (IMP), meropenem (MER) and ceftazidime (CAZ) with EDTA. MBL positives were further confirmed by IMP + EDTA Etest. Twenty strains (42.6%) were found to be MBL producers among the 61 P. aeruginosa. PCR for IMP and VIM MBL was performed on 48 of the 61, 15 were positive for VIM MBL type. CDDT using IMP + EDTA had the highest sensitivity and specificity of 87.8% and 84.4% when compared to Etest, which was higher than the values obtained for CAZ + EDTA and MER + EDTA. CDDT using IMP + EDTA also compared very well with the PCR (specificity = 90.9%, sensitivity = 93.3%). CARB-R among P. aeruginosa is mediated predominantly via MBL production. Clinical P. aeruginosa isolates can be screened routinely using the less expensive IMP + EDTA CDDT in clinical microbiology laboratories.
Keywords: Carbapenem, E test, PCR, Pseudomonas, Resistance
|How to cite this article:|
Manoharan A, Chatterjee S, Mathai D, SARI Study Group. Detection and characterization of metallo beta lactamases producing Pseudomonas aeruginosa. Indian J Med Microbiol 2010;28:241-4
|How to cite this URL:|
Manoharan A, Chatterjee S, Mathai D, SARI Study Group. Detection and characterization of metallo beta lactamases producing Pseudomonas aeruginosa. Indian J Med Microbiol [serial online] 2010 [cited 2020 May 28];28:241-4. Available from: http://www.ijmm.org/text.asp?2010/28/3/241/66486
| ~ Introduction|| |
Pseudomonas aeruginosa isolates are responsible for outbreaks of nosocomial infections in different parts of the world. These isolates have also been responsible for serious infections such as septicemia and pneumonia. P. aeruginosa resistant to carbapenem,  currently the most effective treatment option is being increasingly reported.  Resistance to carbapenems is often mediated by production of Metallo-Beta-Lactamase (MBL), a class B type of beta-lactamases that require bivalent metal ions, usually zinc for their activity. 
P. aeruginosa, producing MBLs, was first reported from Japan in 1991 and since then has been described from various parts of the world, including Asia, Europe, Australia, South America, and North America. , In some countries, P. aeruginosa possessing MBLs constitute nearly 20% of all nosocomial isolates.  In India, published reports indicate the prevalence of MBLs to range from 7-65 %  with a recent study reporting 34% occurrence. 
Several phenotypic methods are available for the detection of MBL-producing bacteria. All these methods are based on the ability of metal chelators, such as EDTA and thiol-based compounds, to inhibit the activity of MBLs. These tests include the double-disk synergy tests using EDTA with imipenem (IMP) or ceftazidime (CAZ), 2-mercaptopropionic acid with CAZ or IMP , Hodge test, a combined disk test using EDTA with CAZ or IMP, the MBL Etest (bioMerieux Marcy l'Etoile, France) , and a microdilution method using EDTA and 1,10-phenanthroline with IMP. 
The double-disk synergy test and Hodge test are often difficult and subjective to interpret. These tests can also be technically demanding and time-consuming, since optimal disk spacing and reincubation of plates are sometimes required to obtain ideal results. Further, 2-mercaptopropionic acid and 1, 10-phenanthroline are toxic for routine handling, and special precautions have to be taken when working with these compounds.  These methods are thus unsuitable for clinical laboratories to perform on a routine basis. So far no studies from India have compared phenotypic and molecular method for screening and confirmation of MBLs. The objective of the present study was to evaluate Combined Disc Diffusion Test (CDDT) with confirmatory Etest and PCR.
| ~ Material and Methods|| |
The study reference laboratory (BMPLIII) received >700 isolates from different centres participating in the seven centre Surveillance of Antimicrobial Resistance Study (SARI) during 2005-2007. From 176 P. aeruginosa strains received, 61 (>80% from respiratory, skin and soft tissue and urine) were selected based on clinical significance and evaluated for CARB-R and MBL production. The strains were confirmed biochemically using standard methods.
Antimicrobial susceptibility testing
Resistance to IMP, MER and CAZ was determined by Kirby Bauer disc diffusion testing with using CAZ (30μg), IMP (10μg), and MER (10μg). The zones of inhibition were interpreted as per CLSI (M100-S15) 2007. The quality control strains used for the study were Escheichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853.
Screening for and confirmation of MBLs
The strains resistant to ceftazidime and carbapenems were screened for MBL by CDDT using CAZ (30mg) + 5ml-0.5M EDTA (930mg), IMP (10mg) + 5ml-0.5 M EDTA(930mg) and MER (10 mg) + 5ml-0.5 M EDTA(930mg). An increase of 7mm or more in zone diameter in the presence of EDTA compared to those with IMP, MER or CAZ tested alone was considered to be a positive test for the presence of an MBL.  MBL production was further confirmed by IMP + IMP-EDTA Etest strips (bioMerieux Marcy l'Etoile, France). Manufacturer's directions were followed for interpretation of results. Additionally colistin Etest was done on MBL- producing P. aeruginosa.
MBL gene identification
DNA template preparation was performed as follows; Fresh Culture of the test organism and the control strains were suspended in 500ml of saline and vortexed to get a uniform suspension. The cells were lysed by heating them at 100°C for ten minutes, and cellular debris was removed by centrifugation at 8000 rpm for five minutes. The supernatant was used as a source of template for amplification. Duplex PCR amplification for the simultaneous detection of IMP and VIM MBL genes were carried out on a Thermal Cycler 9700 instrument (Applied Biosystems, Norwalk, Conn.).The master mix for the PCR was prepared as follows: 2.5ml of PCR buffer, 2.5ml of 25mM MgCl 2 , 2.5ml of 2mM DNTPs, (Fermantas, Glen Brunie, MD) 8.2ml of MilliQ H 2 O, 1ml of each of the forward and the reverse primers and 0.3ml of Taq Polymerase (Fermantas, Glen Brunie, MD). Finally, after dispensing 20ml of the master mix in the individual amplification tubes, 5ml of the extracted DNA was added in the corresponding tubes, the total volume being 25ml. The PCR programme included an initial denaturation step at 94°C for two minutes followed by 30 cycles of DNA denaturation at 94°C for one minute, primer annealing at 54°C for one minute and primer extension at 72°C for one and half minutes with a holding temperature of 72°C for five minutes. After the last cycle the PCR products were stored at 4°C. The PCR products were analyzed by electrophoresis with 1.5% Agarose gels in TBE buffer. The gels were stained with ethidium bromide and the PCR products were visualized under UV light. The primers used for the amplification of the VIM type of MBLs at a concentration of 20 picomolar each were VIM2004A (5'-GTT TGG TCG CAT ATC GCA AC-3') and VIM2004B (5'-AAT GCG CAG CAC CAG GAT AG-3') which amplified a 382-bp amplicon. The primers used for the amplification of the VIM type of MBLs at a concentration of 20 picomolar each were IMP-A (5'-GAA GGY GTT TAT GTT CAT AC-3') and IMP-B (5'-GTA MGT TTC AAG AGT GAT GC-3') which amplified a 587bp amplicon. (Y = C or T and M = A or C).  The presence of VIM and IMP was detected in the clinical isolates of CARB-R P. aeruginosa. C-10(VIM-2) and C-7(IMP-7) were used as positive controls for the study.
| ~ Results|| |
Antimicrobial susceptibility of P. aeruginosa
Among the 61 P. aeruginosa isolates, resistance to CAZ or IMP or MER was 42.6%. These isolates were further tested for MBL production.
Screening for MBLs using EDTA disk screen Tests and MBL Etest
Of the 61 P. aeruginosa clinical isolates included in this study, 20 were confirmed to be MBL producers by the IMP + IMP-EDTA Etest. Among the CDDT combinations, results were more clearly discernable for the IMP + IMP- EDTA combination using the ≥7mm cut off. The mean zone diameter for IMP for MBL producers was 7.35mm and with EDTA was 20.05mm. The non MBLs had a mean zone diameter of 21.66mm for IMP and in combination with EDTA was 22.49mm.
[Table 1] gives the comparison of the three different CDDT combinations against the confirmatory Etest. None of the screening methods showed complete correlation when compared to confirmatory Etest. The IMP + EDTA had the highest specificity and sensitivity for detection of MBLs as compared to the others.
The 20 MBL producers were susceptible to colistin with MIC ranging from 0.5- 0.032ug/ml.
PCR for IMP and VIM
PCR testing detected VIM type of MBL among 15 of the 48 tested isolates; all were negative for IMP MBL gene [Figure 1]. Of the 20 MBLs confirmed by Etest, 17 were available for PCR testing, 15 were VIM positive and two isolates were negative for both IMP and VIM. [Table 2] gives the comparison of CDDT to PCR testing; the IMP + EDTA had higher specificity and sensitivity for detecting MBLs as compared to others.
| ~ Discussion|| |
MBL production is a significant problem in hospital isolates of P. aeruginosa. With increasing isolation of ESBL-producing isolates in the hospital setting necessitating the use of carbapenems, the problem of MBL production is also increasing. The development of simple screening tests designed to detect acquired MBL production is a crucial step towards large scale monitoring of these emerging resistant determinants. Though there are several screening methods recommended for the detection of MBL production, no single test when used alone is specific for these enzymes.
A recent study  has supported the present study findings and recommended use of imipenem and imipenem + EDTA disc diffusion screen. The disc diffusion screen has been further validated against a PCR and has been found to outperform ceftazidime and meropenem EDTA combination. It may not be practically possible for all laboratories to perform the Etest due to cost constraints and availability; however the CDDT should not be very difficult to implement.
In our study, all imipenem-resistant isolates had detectable MBLs, however, there are other resistance mechanisms involved, such as permeability mutations via the loss of porins or the up-regulation of efflux systems, which may be missed by the Etest or the MBL PCR.
We had previously reported novel VIM type of MBL-producing Pseudomonas spp. detected in India during 2006 in which strains were clustered in 33 ribotypes with clones found in multiple hospitals. Several types of VIM-2-carrying integrons were detected including a newly characterized variant, VIM-18 which showed a 4-amino-acid deletion compared to other VIM variants.  The present study also shows that only VIM type of MBL to be present among the study strains.
It is impossible to predict what impact MBL genes will have on the future antimicrobial regimens. There is little doubt that in India the number of MBL possessing P. aeruginosa infections are such that the mainstay antibiotic regimens used to eradicate these bacteria can no longer be relied upon.
Our results support the important role that clinical microbiology laboratories must play to be able to distinguish MBL-producing P. aeruginosa from strains with other mechanisms responsible for carbapenem resistance. The early detection of MBL-producing P. aeruginosa may help in appropriate antimicrobial therapy and avoid the development and dissemination of these multi drug resistant strains. We recommend that all ceftazidime and imipenem/meropenem-resistant P. aeruginosa isolates be routinely screened for MBL production using IMP + IMP-EDTA disk screen test.
| ~ Acknowledgements|| |
Authors are grateful to CIPLA India for funding the SARI study and CMC IRB for approving conduct of this study vide min no.5925 dt 20th June 06. Authors thank Dr.JD.Pitout, University of Calgary, Canada for sharing the quality control strains C-10 (VIM-2) and C-7 (IMP-7) used in this study.
| ~ References|| |
|1.||Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-β-lactamases in a large centralized laboratory. J Clin Microbiol 2005;43: 3129-35. |
|2.||Cirioni O, Ghiselli R, Silvestri C, Kamysz W, Orlando F, Mocchegiani F, et al. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa Strain. Antimicrob Agents Chemother 2007;51:200510. |
|3.||Bush K. ί-Lactamases of increasing clinical importance. Curr Pharm Des 1999;5:839-45. |
|4.||Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM Metallo-ί-lactamase. J Antimicrob Chemother 2003;52:699-702. |
|5.||Lee K, Lee WG, Uh Y, Ha GY, Cho J, Chong Y. VIM- and IMP-type metallo-ί-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg Infect Dis 2003;9:868-71. |
|6.||Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306-25. |
|7.||Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-β-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol 2008;26:233-7. [PUBMED] |
|8.||Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. Carbapenem Resistance among Pseudomonas aeruginosa Strains from India: Evidence for Nationwide Endemicity of Multiple Metallo-β-Lactamase Clones (VIM-2, -5, -6, and -11 and the Newly Characterized VIM-18). Antimicrob Agents Chemother 2009;53:1225-7. |
[Table 1], [Table 2]
|This article has been cited by|
||Colistin, mechanisms and prevalence of resistance
| ||Abed Zahedi Bialvaei,Hossein Samadi Kafil |
| ||Current Medical Research & Opinion. 2015; 31(4): 707 |
|[Pubmed] | [DOI]|
||VIM- and IMP-type metallo-ß-lactamase-producingShigellaspp. in childhood diarrhea from Andaman Islands
| ||Ramanathan Thamizhmani,Ramya Rhagavan,Sugunan Attayur Purushottaman,Vijayachari Paluru |
| ||Infectious Diseases. 2015; : 1 |
|[Pubmed] | [DOI]|
||Antibiotic Resistance Pattern and Evaluation of Metallo-Beta Lactamase Genes Including bla-IMP and bla-VIM Types in Pseudomonas aeruginosa Isolated from Patients in Tehran Hospitals
| ||Samira Aghamiri,Nour Amirmozafari,Jalil Fallah Mehrabadi,Babak Fouladtan,Hossein Samadi Kafil |
| ||ISRN Microbiology. 2014; 2014: 1 |
|[Pubmed] | [DOI]|
||Molecular investigation of carbapenem resistance among multidrug-resistantPseudomonas aeruginosaisolated clinically in Thailand
| ||Piyatip Khuntayaporn,Preecha Montakantikul,Pitak Santanirand,Pattarachai Kiratisin,Mullika Traidej Chomnawang |
| ||Microbiology and Immunology. 2013; 57(3): 170 |
|[Pubmed] | [DOI]|
||ESBL and MBL mediated resistance in Pseudomonas aeruginosa: An emerging threat to clinical therapeutics
| ||Peshattiwar, P.D., Peerapur, B.V. |
| ||Journal of Clinical and Diagnostic Research. 2011; 5(8): 1552-1554 |